M

Maze Therapeutics Inc
NASDAQ:MAZE

Watchlist Manager
Maze Therapeutics Inc
NASDAQ:MAZE
Watchlist
Price: 38.86 USD -1.79%
Market Cap: 1.9B USD

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of MAZE.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MAZE Intrinsic Value
Not Available
M
Base Case Scenario
Compare MAZE to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about MAZE?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Maze Therapeutics Inc

Balance Sheet Decomposition
Maze Therapeutics Inc

Current Assets 391.3m
Cash & Short-Term Investments 383.9m
Other Current Assets 7.4m
Non-Current Assets 30.8m
PP&E 26.5m
Other Non-Current Assets 4.3m
Current Liabilities 22.1m
Accounts Payable 2.9m
Accrued Liabilities 19.2m
Non-Current Liabilities 20.5m
Other Non-Current Liabilities 20.5m
Efficiency

Free Cash Flow Analysis
Maze Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Maze Therapeutics Inc

Revenue
0 USD
Operating Expenses
-99.2m USD
Operating Income
-99.2m USD
Other Expenses
30.5m USD
Net Income
-68.7m USD
Fundamental Scores

MAZE Profitability Score
Profitability Due Diligence

Maze Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Negative 3Y Average Net Margin
Negative 3Y Average Operating Margin
Negative ROE
24/100
Profitability
Score

Maze Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

MAZE Solvency Score
Solvency Due Diligence

Maze Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Maze Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MAZE Price Targets Summary
Maze Therapeutics Inc

Wall Street analysts forecast MAZE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MAZE is 44.12 USD with a low forecast of 34.34 USD and a high forecast of 63 USD.

Lowest
Price Target
34.34 USD
12% Downside
Average
Price Target
44.12 USD
14% Upside
Highest
Price Target
63 USD
62% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Maze Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MAZE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

MAZE Insider Trading
Buy and sell transactions by insiders

MAZE News

Other Videos